KIT and ovarian neoplasm: If we accept the proposed model for regulation of IDO expression and Treg generation as a working hypothesis, we can infer that agents with the ability to inhibit c-KIT/PI3K/AKT/mTOR signaling or otherwise modify myeloid cell function may reduce IDO activity and inhibit recruitment of Treg in the ovarian tumor micro-environment.